Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by Packerfan666on Dec 27, 2018 4:04pm

140 Views

Post# 29161169

Defintely Annoying and Frustrating but

Hey Guys.. I am with you. This is immensely frustrating! But here is what I am holding on to. 2 more news releases coming shortly. Also results on low dose were exceptional! Medium and high dose to follow and then we are almost at phase 3. Then no one can hold us down. We all know this is crazy cheap. Reason is a two recent bad financing and having to pay Salzman in shares which he then has to dump in 10 days. Recipe for disaster at the end of year when tax selling is rampant and people are generally lackadaisical in the market. Hang tight and better days are coming. Much better. IMO

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading